Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Xiao-Na Wang, Xiao-Xuan Su, Sui-Qi Cheng, Zhi-Yin Sun, Zhi-Shu Huang & Tian-Miao Ou. (2019) MYC modulators in cancer: a patent review. Expert Opinion on Therapeutic Patents 29:5, pages 353-367.
Read now
Read now
Maria Giuseppina Cabras & Emanuele Angelucci. (2015) Ibrutinib: another weapon in our arsenal against lympho-proliferative disorders. Expert Opinion on Pharmacotherapy 16:18, pages 2715-2718.
Read now
Read now
Articles from other publishers (24)
Mohamed A. Abdelgawad, Nadia A.A. Elkanzi, A.A. Nayl, Arafa Musa, Nasser Hadal Alotaibi, W.A.A. Arafa, Sobhi M. Gomha & Rania B. Bakr. (2022) Targeting tumor cells with pyrazolo[3,4-d]pyrimidine scaffold: A literature review on synthetic approaches, structure activity relationship, structural and target-based mechanisms. Arabian Journal of Chemistry 15:5, pages 103781.
Crossref
Crossref
Liangliang Ren, Ling Li, Lei Zhang, Xin Li, Xiaorui Fu, Xinhua Wang, Jingjing Wu, Zhenchang Sun, Xiaoyan Feng, Yu Chang, Zhiyuan Zhou, Feifei Nan, Jiaqin Yan, Fei Kong & Mingzhi Zhang. (2021) Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study. Indian Journal of Hematology and Blood Transfusion 38:1, pages 42-50.
Crossref
Crossref
Mohammed I. El-Gamal, Nada H. Mewafi, Nada E. Abdelmotteleb, Minnatullah A. Emara, Hamadeh Tarazi, Rawan M. Sbenati, Moustafa M. Madkour, Seyed-Omar Zaraei, Afnan I. Shahin & Hanan S. Anbar. (2021) A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors. Molecules 26:23, pages 7376.
Crossref
Crossref
Donald J. AbrahamMingfeng Yu, Solomon Tadesse & Shudong Wang. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
65
.
Narpati Wesa Pikatan, Yen-Lin Liu, Oluwaseun Adebayo Bamodu, Michael Hsiao, Wen-Ming Hsu, Sofia Mubarika Haryana, Sutaryo, Tsu-Yi Chao & Chi-Tai Yeh. (2020) Aberrantly expressed Bruton’s tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells. Cellular Oncology 43:6, pages 1067-1084.
Crossref
Crossref
Nagarjun Rangaraj, Sravanthi Reddy Pailla, Saurabh Shah, Shubham Prajapati & Sunitha Sampathi. (2020) QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach. Drug Delivery and Translational Research 10:5, pages 1476-1494.
Crossref
Crossref
Fanny Gallais, Loïc Ysebaert, Fabien Despas, Sandra De Barros, Loïc Dupré, Anne Quillet-Mary, Caroline Protin, Fabienne Thomas, Lucie Obéric, Ben Allal, Etienne Chatelut & Mélanie White-Koning. (2020) Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. Clinical Pharmacokinetics 59:9, pages 1171-1183.
Crossref
Crossref
Sumirtha Balaratnam & John S. SchneeklothJr.Jr.. 2020. Quadruplex Nucleic Acids As Targets For Medicinal Chemistry. Quadruplex Nucleic Acids As Targets For Medicinal Chemistry
361
407
.
Nagarjun Rangaraj, Sravanthi Reddy Pailla, Paramesh Chowta & Sunitha Sampathi. (2019) Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability. AAPS PharmSciTech 20:8.
Crossref
Crossref
Patrice Cagle, Suryakant Niture, Anvesha Srivastava, Malathi Ramalinga, Rasha Aqeel, Leslimar Rios-Colon, Uchechukwu Chimeh, Simeng Suy, Sean P. Collins, Rajvir Dahiya & Deepak Kumar. (2019) MicroRNA-214 targets PTK6 to inhibit tumorigenic potential and increase drug sensitivity of prostate cancer cells. Scientific Reports 9:1.
Crossref
Crossref
Hui Zhang & Longhui Qiu. 2019. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
109
124
.
Yakup Batlevi & Craig S. Sauter. 2019. Cell and Gene Therapies. Cell and Gene Therapies
93
108
.
Femina Rauf, Fernanda Festa, Jin G. Park, Mitchell Magee, Seron Eaton, Capria Rinaldi, Carlos Morales Betanzos, Laura Gonzalez-Malerva & Joshua LaBaer. (2018) Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner. Oncogene 37:17, pages 2237-2250.
Crossref
Crossref
Anne B. Satterthwaite. (2018) Bruton’s Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus. Frontiers in Immunology 8.
Crossref
Crossref
Harriet S. Walter, Sandrine Jayne, Simon A. Rule, Guillaume CartronFranck Morschhauser, Salvador Macip, Lionel KarlinCeri Jones, Charles HerbauxPhilippe QuittetNimish ShahClaire V. HutchinsonChristopher Fegan, Yingsi Yang, Siddhartha Mitra, Gilles Salles & Martin J. S. Dyer. (2017) Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059. Blood 129:20, pages 2808-2810.
Crossref
Crossref
Jennifer Alfaro, Felipe Pérez de Arce, Sebastián Belmar, Glenda Fuentealba, Patricio Avila, Gonzalo Ureta, Camila Flores, Claudia Acuña, Luz Delgado, Diana Gaete, Brahmam Pujala, Anup Barde, Anjan K. Nayak, T. V. R. Upendra, Dhananjay Patel, Shailender Chauhan, Vijay K. Sharma, Stacy Kanno, Ramona G. Almirez, David T. Hung, Sarvajit Chakravarty, Roopa Rai, Sebastián Bernales, Kevin P. Quinn, Son M. Pham & Emma McCullagh. (2017)
Dual Inhibition of Bruton’s Tyrosine Kinase and Phosphoinositide-3-Kinase p110
δ
as a Therapeutic Approach to Treat Non-Hodgkin’s B Cell Malignancies
. Journal of Pharmacology and Experimental Therapeutics 361:2, pages 312-321.
Crossref
Crossref
Haleigh Mistry, Sheryl Forbes & Nathan Fowler. (2017) Toxicity Management: Development of a Novel and Immune-Mediated Adverse Events Algorithm
. Clinical Journal of Oncology Nursing 21:2, pages 53-59.
Crossref
Crossref
Ilaria Iacobucci. (2017) Targeting precursor BCR signaling in ALL. Blood 129:9, pages 1062-1064.
Crossref
Crossref
Jonathan R. Whitfield, Marie-Eve Beaulieu & Laura Soucek. (2017) Strategies to Inhibit Myc and Their Clinical Applicability. Frontiers in Cell and Developmental Biology 5.
Crossref
Crossref
David A. Fruman & Susan O'Brien. (2017) A targeted treatment with off-target risks. Nature 542:7642, pages 424-425.
Crossref
Crossref
Sarah Levinson & Ross L. Cagan. (2016) Drosophila Cancer Models Identify Functional Differences between Ret Fusions. Cell Reports 16:11, pages 3052-3061.
Crossref
Crossref
Amy K. LeBlanc, Christina N. Mazcko & Chand Khanna. (2016) Defining the Value of a Comparative Approach to Cancer Drug Development. Clinical Cancer Research 22:9, pages 2133-2138.
Crossref
Crossref
Harriet S. Walter, Simon A. RuleMartin J. S. Dyer, Lionel KarlinCeri JonesBruno CazinPhilippe QuittetNimish ShahClaire V. HutchinsonHideyuki Honda, Kevin Duffy, Joseph Birkett, Virginia Jamieson, Nigel Courtenay-Luck, Toshio Yoshizawa, John Sharpe, Tomoya Ohno, Shinichiro Abe, Akihisa Nishimura, Guillaume CartronFranck MorschhauserChristopher FeganGilles Salles. (2016) A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood 127:4, pages 411-419.
Crossref
Crossref
Alison YeomansStephen M. ThirdboroughBeatriz Valle-ArgosAdam LinleySergey KrysovMarina Sanchez HidalgoElodie LeonardMuhammad IshfaqSimon D. WagnerAnne E. WillisAndrew J. SteeleFreda K. StevensonFrancesco Forconi, Mark J. Coldwell & Graham Packham. (2016) Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation. Blood 127:4, pages 449-457.
Crossref
Crossref